Bayer Valuation
Is BAYN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BAYN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BAYN (€19.13) is trading below our estimate of fair value (€119.94)
Significantly Below Fair Value: BAYN is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BAYN?
Key metric: As BAYN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is BAYN's PS Ratio? | |
|---|---|
| PS Ratio | 0.4x |
| Sales | €46.74b |
| Market Cap | €18.82b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | 5.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BAYN's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.9x | ||
THQM Tchaikapharma High Quality Medicines AD | 32x | n/a | лв1.6b |
SFA Sopharma AD | 0.5x | n/a | лв928.1m |
TEVA Teva Pharmaceutical Industries | 1.1x | 2.5% | US$18.8b |
SDZ Sandoz Group | 2x | 5.7% | CHF 17.8b |
BAYN Bayer | 0.4x | 1.0% | €18.8b |
Price-To-Sales vs Peers: BAYN is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (9x).
Price to Sales Ratio vs Industry
How does BAYN's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Sales vs Industry: BAYN is good value based on its Price-To-Sales Ratio (0.4x) compared to the European Pharmaceuticals industry average (2.9x).
Price to Sales Ratio vs Fair Ratio
What is BAYN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BAYN's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €19.13 | €28.16 +47.1% | 22.0% | €45.10 | €22.00 | n/a | 20 |
| Nov ’25 | n/a | €34.75 0% | 30.7% | €68.00 | €25.00 | n/a | 20 |
| Oct ’25 | n/a | €34.24 0% | 30.7% | €68.00 | €25.00 | n/a | 21 |
| Sep ’25 | n/a | €35.41 0% | 34.1% | €68.00 | €25.00 | n/a | 22 |
| Aug ’25 | n/a | €35.82 0% | 33.5% | €68.00 | €25.00 | n/a | 22 |
| Jul ’25 | n/a | €36.18 0% | 32.9% | €68.00 | €25.00 | n/a | 22 |
| Jun ’25 | €27.76 | €36.64 +32.0% | 32.9% | €68.00 | €25.00 | n/a | 22 |
| May ’25 | n/a | €36.90 0% | 33.3% | €68.00 | €25.00 | n/a | 21 |
| Apr ’25 | n/a | €37.60 0% | 33.0% | €68.00 | €25.00 | n/a | 20 |
| Mar ’25 | €28.18 | €43.48 +54.3% | 30.0% | €75.00 | €25.00 | n/a | 21 |
| Feb ’25 | €32.57 | €47.67 +46.4% | 30.6% | €86.00 | €25.00 | n/a | 21 |
| Jan ’25 | n/a | €50.32 0% | 28.5% | €86.00 | €25.00 | n/a | 22 |
| Dec ’24 | €30.95 | €54.68 +76.7% | 27.3% | €90.00 | €36.00 | n/a | 22 |
| Nov ’24 | €40.62 | €64.13 +57.9% | 18.3% | €90.00 | €43.00 | n/a | 22 |
| Oct ’24 | €45.14 | €65.89 +46.0% | 18.4% | €90.00 | €43.00 | n/a | 21 |
| Sep ’24 | n/a | €66.71 0% | 16.6% | €90.00 | €45.00 | n/a | 21 |
| Aug ’24 | n/a | €68.62 0% | 18.1% | €97.00 | €45.00 | n/a | 21 |
| Jul ’24 | €50.66 | €73.00 +44.1% | 16.2% | €97.00 | €57.00 | n/a | 20 |
| Jun ’24 | n/a | €72.85 0% | 15.9% | €97.00 | €57.00 | €27.76 | 21 |
| May ’24 | n/a | €74.31 0% | 16.1% | €100.00 | €57.00 | n/a | 22 |
| Apr ’24 | n/a | €74.45 0% | 16.2% | €100.00 | €57.00 | n/a | 22 |
| Mar ’24 | n/a | €74.30 0% | 16.5% | €99.00 | €54.00 | €28.18 | 23 |
| Feb ’24 | n/a | €73.99 0% | 18.0% | €106.00 | €54.00 | €32.57 | 23 |
| Jan ’24 | n/a | €76.67 0% | 17.4% | €106.00 | €54.00 | n/a | 22 |
| Dec ’23 | €55.13 | €77.99 +41.5% | 15.9% | €106.00 | €54.00 | €30.95 | 22 |
| Nov ’23 | €51.58 | €77.41 +50.1% | 19.2% | €106.00 | €37.06 | €40.62 | 22 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Evotec
€1.6b
Operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
EVT
€8.82
7D
0%
1Y
n/a
Valneva
€299.7m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
AYJ
€2.08
7D
0%
1Y
-60.1%
Tilray Brands
US$1.5b
A lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally.
2HQ
US$1.58
7D
0%
1Y
n/a